Evolving significance of prognostic markers associated with treatment improvement in patients with Stage 4 neuroblastoma Academic Article Article uri icon

Overview

MeSH Major

  • Antibodies, Bispecific
  • Antigens, Neoplasm
  • Antineoplastic Agents
  • Carcinoma, Hepatocellular
  • Immunotherapy
  • Liver Neoplasms
  • Receptors, Antigen
  • Recombinant Fusion Proteins

abstract

  • Because patient survival improves with more effective therapy, traditional prognostic markers, such as age, MYCN amplification, and elevated serum LDH levels, have become less important for patients with Stage 4 NB. In the current study, less common chromosomal abnormalities (LOH at 1p22 and 11q23) appeared to assume new importance.

publication date

  • May 15, 2002

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/cncr.10548

PubMed ID

  • 12173347

Additional Document Info

start page

  • 2756

end page

  • 65

volume

  • 94

number

  • 10